Effective antihypertensive therapy – a combination of ACE inhibitors and calcium antagonists in the combined preparation Review article
Article Sidebar
Main Article Content
Abstract
The prevalence of hypertension and its poor control requires a simple and effective therapeutic tools. It seems that in the near future, this role will play combined drugs. They are characterized by a higher efficiency than the antihypertensive drugs at the same doses used separately. Combined drugs are also better tolerated and less expensive than separate components. One of the most effective combined drugs is combination of ACE-I and calcium channel blockers. Both groups of drugs have been tested in different patient populations in large controlled studies. It has been shown that a combined drug containing both components effectively lowers blood pressure and is well tolerated.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Feldman R.D., Zou G.Y., Vandervoort M.K. et al.: A simplified approach to the treatment of uncomplicated hypertension: A Cluster, randomized, controlled trial. Hypertension 2009; 53(4): 646-653.
3. Dahlof B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
4. Jamerson K., Weber M.A., Bakris G.L.; for the ACCOMPLISH trial investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359 (23): 2417-2428.
5. Bahl V.K., Jadhav U.M., Thacker H.P.: Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am. J. Cardiovasc. Drugs 2009; 9: 135-142.
6. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
7. Fox K.M.: European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery diseased: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 2003; 362: 782-788.
8. ADVANCE Collaborative Group: ADVANCE – Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine 2005; 22: 1-7.